Follow
Tumor associated macrophages
Tumor associated macrophages (TAMs) are a subset of myeloid-derived immune cells that cause immunosuppression in a tumor microenvironment. TAMS produce cytokines, chemical messengers that regulate immune responses, that inhibit the anti-tumor immune response thus promoting tumor growth and development.
FEB 09, 2021 | 9:00 AM
Date: February 9, 2020 Time: 9:00am (PST), 12:00pm (EST) 90% of breast cancer mortality is caused by distant metastasis, a process that involves both dissemination of cancer cells to distant...
OCT 20, 2020 | 9:00 AM
DATE: October 20th, 2020 TIME: 08:00am PT, 11:00am ET Tumor-associated macrophages (TAMs) are key cells in the tumor microenvironment (TME) with diverse immune functions that have a major in...
SEP 23, 2020 | 12:00 PM
B cells and tertiary lymphoid structures (TLS) promote immunotherapy response 1:00–1:30 pm PDT Presented By: Rafet Basar, MD...
SEP 17, 2020 | 11:00 AM
In less than nine months, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has killed hundreds of thousands of people, including >23,000 in New York City (NYC) alone. The...
SEP 01, 2020 | 8:00 AM
DATE: September 1, 2020 TIME: 8:00am PT, 11:00am ET Nearly half of all cancer patients are eligible to receive treatment with immune checkpoint inhibitors (ICI). Thus, preventing, identifyin...
JUL 07, 2020 | 11:00 AM
Immune escape mechanisms such as the induction/recruitment of immunosuppressive cells and the increased expression of various immunosuppressive molecules including PD-1/PD-1 ligands are esse...
JUL 07, 2020 | 6:00 AM
Brain malignancies can either originate from within the CNS (gliomas) or invade from other locations in the body (metastases). A highly immunosuppressive tumor microenvironment (TME) influen...
MAY 20, 2020 | 12:45 PM
Background: Despite the immunogenicity and safety profile of dendritic cell (DC) vaccines, the importance of vaccine-induced antigen-specific T cell responses is unclear across clinical tria...
MAY 19, 2020 | 11:45 AM
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
MAY 19, 2020 | 11:15 AM
Background: Growing evidence supports the critical role of preexisting immune response in triple negative breast cancer (TNBC). However, there are limitations with current evaluation approac...
